31results about How to "Reduce dosing frequency" patented technology

The invention discloses composite hydrogel as well as a preparation method and application thereof. The curcumin-EGCG composite hydrogel is prepared by forming a complex through hydrogen-bond interaction between gelatin and epigallocatechin gallate and carrying out chemical crosslinking through Schiff base reaction of curcumin and gelatin. The composite hydrogel disclosed by the invention has a self-healing characteristic or viscosity and a shear thinning characteristic, and is beneficial to local application. The composite hydrogel is loose and porous in structure, the drug loading rate can be increased, the drug can be slowly and controllably released, the treatment effect of the composite hydrogel in androgenetic alopecia is promoted, meanwhile, the solubility of a drug monomer can be remarkably improved, and the problem that the drug solubility is low is solved. The composite hydrogel provided by the invention provides an effective transdermal drug delivery preparation for treatment of skin diseases, and has good clinical application prospects and development values.

The invention relates to hydrogel for treating ischemic brain injury and a preparation method thereof. The hydrogel is prepared from the following raw materials: methylacryloylated hyaluronic acid, methylacryloylated gelatin, curcumin loaded HA-PPS (Hydroxypropyl-Polyphenylene Sulfite) nano-micelles and dendrobium polysaccharide loaded sodium alginate microspheres. Through combination of a nanotechnology and an intelligent response material, HA-PPS is adopted to load curcumin and sodium alginate microspheres are adopted to encapsulate dendrobium polysaccharide, so that the drug activity can be more effectively protected, the drug is protected to penetrate through a blood brain barrier and be accurately delivered to a brain injury area, and targeted release of the drug is realized; the anti-oxidation and anti-inflammatory effects are better under the combined action of the curcumin and the dendrobium polysaccharides, and meanwhile, a slow release function is also achieved.

The invention belongs to the technical field of veterinary preparations, and particularly relates to a tilmicosin premix and a preparation method thereof. The tilmicosin premix is prepared from the following raw materials: tilmicosin, a polylactic acid-glycolic acid copolymer, lecithin, modified hydroxypropyl methyl cellulose, grafted polyvinylpyrrolidone, polyethylene glycol and an antioxidant, a solid dispersion is formed through lecithin and grafted polyvinylpyrrolidone, the solubility and stability of tilmicosin are enhanced, polylactic acid-glycolic acid copolymer nano-microspheres are prepared through a double-emulsion solvent evaporation method, slow release of drugs is achieved, dodecyl modified hydroxypropyl methyl cellulose and polyethylene glycol are combined, and the sustained release effect is achieved. The solubility and the slow release characteristic are further enhanced. The activity of the granular premix is effectively preserved, and the granular premix is convenient to use and transport.

The invention provides an application of a recombinant XVII type humanized collagen or a composition containing the recombinant XVII type humanized collagen in preparation of a preparation for preventing and / or treating lupus erythematosus, which can overcome the defect that more adverse reactions are generated in treatment in the existing scheme.

The invention discloses a gene engineering exosome and a slow release method and application thereof, the gene engineering exosome is derived from human adipose-derived stem cells, si-tgfbr2 is loaded in the gene engineering exosome, the si-tgfbr2 is specific siRNA aiming at a Tgfbr2 gene, and the gene engineering exosome can regulate and control proliferation of VSMCs, inhibit transformation of the VSMCs from a contraction phenotype to a synthetic phenotype when the VSMCs are stimulated, and inhibit the growth of the VSMCs. According to the present invention, the gene engineering exosome can be used to maintain the normal structure and the function of the blood vessel, and the sustained release effect of the content in the gene engineering exosome can be achieved by wrapping the gene engineering exosome in the PHA biodegradable material, such that the local treatment concentration can be easily stabilized, the drug administration frequency can be easily reduced, the lasting time of the treatment effect can be easily prolonged, and the treatment gene can be effectively delivered to the target cell; the treatment effect is improved; when being used for modifying a small-caliber artificial blood vessel, the small-caliber artificial blood vessel can be improved in biocompatibility and functionality, and can be prevented from being implanted into the blood vessel for remodeling unbenign hyperplasia stenosis; the invention not only provides a new thought and method for the treatment of vascular diseases, but also has important clinical application value and popularization prospect.

The invention discloses a novel polypeptide, a polypeptide derivative and application thereof, and belongs to the technical field of biological medicine. The invention specifically relates to a specific sequence, a discovery process, a specific anti-tumor type, a long-acting modification mode and application of the novel polypeptide. The tumors comprise one or more of brain glioma, neuroblastoma, head and neck cancer, esophagus cancer, thyroid cancer, lung cancer, liver cancer, kidney cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, colon cancer, small intestinal cancer, ileocecum cancer, stomach cancer, bladder cancer, pancreatic cancer, prostate cancer, bile duct cancer, melanoma, sarcoma, myeloma, lymphoma and leukemia; the compound has the specific effect of inhibiting proliferation and / or metastasis of tumor cells, is wide in treatment spectrum and has important treatment value in various tumors.

The invention discloses a drug-guided anti-inflammatory enhanced mesenchymal stem cell preparation as well as a preparation method and application thereof. By constructing the medicine-loaded mesenchymal stem cell preparation, the immunosuppression capacity of the mesenchymal stem cells is improved, the angiogenesis capacity of the mesenchymal stem cells is reduced, meanwhile, by releasing the glucocorticoid medicine at a low dosage, the side effect of single administration is avoided, M2 type macrophage polarization is induced, the inflammatory state of cartilage cells is improved, and the effect of treating the cartilage cells is achieved. The curative effect of the mesenchymal stem cells on osteoarthritis is improved in multiple aspects, and the mesenchymal stem cells are proved in animal bodies. The drug-guided anti-inflammatory enhanced mesenchymal stem cell preparation provides a new thought for the treatment of osteoarthritis.

The present invention discloses a diquafosol composition, a pharmaceutical preparation containing the same and an application thereof. The present invention provides a diquafosol resin composition, which comprises diquafosol or a pharmaceutically acceptable salt thereof, an anion exchange resin and water. The diquafosol composition provided by the present invention has a high drug adsorption rate and drug loading, can achieve controlled release of the drug, improve the bioavailability of the drug, and is conducive to the drug exerting a stable and sustained therapeutic effect.

The invention provides a kind of compound lidocaine gel and preparation method thereof, belong to the technical field of pharmaceutical preparations, the compound lidocaine gel, by weight, comprises the following components: 0.02-0.04 parts of prednisolone acetate, 0.08-0.2 parts of lidocaine hydrochloride, 10-25 parts of dimethyl sulfoxide, 0.05-3 parts of cross-linking agent, 0.01-3 parts of pH adjusting agent, 0.02-2 parts of stabilizer, 0.02-0.05 parts of preservative, 0.4-2 parts of penetrant, 0.5-5 parts of tackifier, 5-8 parts of gel skeleton material, 10-20 parts of humectant, 20-50 parts of purified water. The compound lidocaine gel provided by the invention has the characteristics of good bioavailability, fast absorption and onset, stable quality, no irritation to skin, etc., and the preparation process of the compound lidocaine gel is simple, and it is suitable for amplification production application.

A human interleukin 2-polyethylene glycol conjugate and use thereof. The human interleukin 2-polyethylene glycol conjugate comprises a recombinant human interleukin 2 containing at least one unnatural amino acid and PEG coupled to the at least one unnatural amino acid. The unnatural amino acid is a compound containing a carbonyl terminal group and having a structure as shown in formula (I) or an enantiomer thereof, and the PEG is coupled to the at least one unnatural amino acid by forming an oxime bond between the carbonyl terminal group and the PEG containing a hydroxylamine terminal group. The human interleukin 2-polyethylene glycol conjugate can be used individually or in combination with other anti-tumor drugs for the treatment of diseases such as solid tumors and hematologic tumors.

The present invention relates to a composition for preventing or treating cancer, comprising a dual expression vector, and more specifically, to a method for effectively treating cancer by simultaneously inducing the actions of cancer metabolism drugs and cancer immunotherapy drugs by using a dual expression vector for simultaneously expressing an HIF-1α inhibitor and anticancer cytokines.

The invention discloses a sugar-responsive insulin analogue as well as a preparation method and application thereof. Specifically, the invention discloses a sugar responsive insulin analogue, which is insulin modified by a structure as shown in a formula I. The modification means that one or more amino groups in the insulin are connected with the structure as shown in the formula I. In the formula I, A is an active structure fragment of a glucose transporter inhibitor, and m is 1-20. The sugar-responsive insulin analogue disclosed by the invention can realize intelligent sugar response adjustment, has a longer half-life period and a wider therapeutic window compared with the existing insulin, and can reduce the introduction of materials and reduce the administration frequency. # imgabs0 #

The present invention relates to a human granulocyte colony stimulating factor derivative modified by a fat chain, which is derived from the site-specific modification of the free cysteine ​​residue of the human granulocyte colony stimulating factor by a fat chain-maleimide, and the preparation method thereof comprises the synthesis of the fat chain-maleimide, the synthesis of the human granulocyte colony stimulating factor derivative modified by the fat chain, and the separation, purification and characterization of the product. Compared with the unmodified human granulocyte colony stimulating factor, the human granulocyte colony stimulating factor derivative modified by the fat chain has a high in vitro activity retention rate, a prolonged sustained action time in the body of the experimental animal, a reduced frequency of administration, and an improved drug bioavailability and efficacy.

The invention provides a sustained-release fluorocalcitriol tablet and a preparation method thereof, and relates to the technical field of pharmaceutical preparations, the preparation raw materials comprise a sustained-release skeleton layer prepared from a fluorocalcitriol-containing drug core particle and a controlled-release film coating solution containing a methacrylate copolymer, the preparation method comprises the following steps: preparing the medicine core, preparing the controlled-release film coating solution and coating, preparing the controlled-release skeleton layer, and drying and packaging.

This invention discloses a nystatin microsphere with targeted enhanced antifungal function, its preparation method, and its application. The microsphere uses sodium alginate as a carrier, internally encapsulating the antifungal drug nystatin. The surface is covalently modified with the β-glucan binding domain of the Dectin-1 protein, constructing a smart drug delivery system with fungal targeting function. The microsphere preparation process is simple and reproducible, and can be scalable using an emulsion-ionic crosslinking method combined with protein coupling technology. In vitro characterization shows that the microspheres have uniform particle size and stable dispersion, and Dectin-1 modification significantly enhances their specific binding ability against Candida albicans. This targeted delivery system, while successfully preserving drug activity, significantly improves the antifungal efficiency of nystatin through Dectin-1-mediated targeting, achieving efficacy close to that of free drug, and providing a new strategy for constructing highly efficient and long-acting antifungal agents.

This invention relates to the fields of biomedicine and nanomaterials technology, and provides a bilayer core-shell nanoparticle composite thermosensitive gel for postoperative analgesia, its preparation method, and its applications. The bilayer core-shell nanoparticles comprise: a core of PLGA nanoparticles loaded with magnesium, and a shell of a lipid bilayer loaded with bupivacaine. The composite thermosensitive gel is made by uniformly dispersing the bilayer core-shell nanoparticles in a thermosensitive gel material. By constructing a structure with a lipid shell loaded with bupivacaine and a PLGA core loaded with magnesium, and combining it with a thermosensitive gel, this invention achieves rapid release of bupivacaine for acute postoperative analgesia, and sustained slow release of magnesium ions for long-term anti-inflammatory and repairing effects. This perfectly meets the temporal requirements of postoperative pain management and has broad clinical application prospects.

The invention discloses a fusion polypeptide RAT-1 and application thereof in hypertension treatment. The topological structure of the fusion polypeptide is a kidney targeting head-ACE2 functional segment-MMP responsive connexon-AT1 receptor antagonism segment, and the full-length sequence is as shown in SEQ ID No: 1. The kidney targeting head can be specifically combined with megalin receptors of renal tubular epithelial cells to realize kidney targeting delivery; the ACE2 functional segment can efficiently degrade angiotensin II; the MMP responsive connexon is specifically cut in a focus microenvironment, and an AT1 receptor antagonism segment is released; the AT1 receptor antagonist segment can block the receptor signal channel of angiotensin II. The fusion polypeptide has good plasma stability, shows a powerful and long-acting antihypertensive effect in a spontaneous hypertension rat model, is remarkable in kidney targeting, and can relieve renal fibrosis and protect podocyte functions. The fusion polypeptide disclosed by the invention realizes a synergistic effect of targeted delivery, enzymolysis catalysis, response release and receptor antagonism, and can be used for preparing hypertension treatment medicines and kidney protection medicines.

The invention relates to the technical field of medical drug preparation, in particular to a total glucosides of paeony nano preparation for treating inflammatory diseases and a preparation method of the total glucosides of paeony nano preparation. The nanogel dispersoid is formed by self-assembling molecules in a water phase through thermal induction gelatinization and a subsequent cooling process; the mass ratio of the total glucosides of paeony to the starch is (1: 10)-(1: 50); the average hydrated particle size of gel particles in the nanogel dispersion ranges from 80 nanometers to 300 nanometers, and the polydispersity index of the gel particles is smaller than 0.3. According to the total glucosides of paeony nano preparation for treating inflammatory diseases and the preparation method thereof, the process is simple, the cost is low, complicated equipment or organic solvents are not needed, the preparation is very suitable for industrial production, edible starch is taken as a carrier material, the biocompatibility is excellent, the safety is high, the enrichment of medicines at inflammatory parts can be effectively improved, the action time can be prolonged, and the application prospect is wide. Therefore, curative effect is improved, and administration frequency is reduced.

The invention discloses a preparation method of pH gradient active drug loading type maqui berry anthocyanin-curcumin compound lipidosome, belongs to the fields of biological medicines, food science and nutritional health-care products, and particularly relates to a nano drug delivery system and preparation of functional foods and dietary supplements. According to the method, the water-soluble maqui berry anthocyanin and the fat-soluble curcumin are efficiently entrapped at the same time by utilizing a unique double-layer structure of the lipidosome and through a film dispersion-hydration technology. Soybean lecithin and cholesterol are used as main membrane materials, tea polyphenol or vitamin E and other antioxidants are combined, and curcumin is induced to transmembrane-transfer from a lipid bilayer membrane to an internal water phase through precise pH gradient control and mild heating, so that the encapsulation efficiency of curcumin is remarkably improved. Then, through the steps of high-pressure microjet homogenization, low-temperature dialysis and the like, the maqui berry anthocyanin-curcumin compound liposome which is uniform in particle size, high in stability and excellent in encapsulation efficiency is prepared.

The present invention discloses an antigen-specific B cell vaccine and its application, the vaccine is prepared by B cells obtained after sorting of collagen-induced arthritis mouse spleen cells; the B cells obtained after sorting are total B cells, Plasma cells or pathogenic B cells; the preparation method is that the B cells obtained after sorting are cultured under the stimulation of anti-CD40, CpG, type II collagen (CII) and BAFF, and then irradiated by a cobalt source to obtain the vaccine. The present invention also discloses a human antigen-specific B cell vaccine, which is prepared by replacing the above-mentioned collagen-induced arthritis mouse spleen cells with peripheral blood cells of rheumatoid arthritis patients. Compared with traditional drugs, the B cell vaccine of the present invention has a smaller dosage, a lower frequency of administration, and a longer maintenance period; subcutaneous injection, simple and convenient; treatment of diseases by immunomodulation; can effectively control the condition, reduce bone erosion and joint destruction; autologous reinfusion, no immune tolerance problems; small side effects.

The invention discloses a breast cancer antibody drug conjugate based on a targeted HER2 receptor and application of the breast cancer antibody drug conjugate in the technical field of antibody drug conjugates, the breast cancer antibody drug conjugate comprises a monoclonal antibody, the monoclonal antibody is coupled with a cytotoxic drug through a polymer, the monoclonal antibody is trastuzumab, and the monoclonal antibody is an HER2 receptor. The cytotoxic drug is maytansine DM1 with a tubulin synthesis inhibition effect, the polymer comprises a polyaspartic acid chain, a plurality of maleimide groups are grafted on side branch carboxyl of the polyaspartic acid chain, and Fc-III-4C peptide in the polymer is combined with an Fc segment of trastuzumab through a high affinity effect, so that the polymer can be used for inhibiting microtubulin synthesis. And the monoclonal antibody-polymer-cytotoxic drug conjugate T-NPLA-DM1 is formed by using the monoclonal antibody-polymer-cytotoxic drug conjugate. The antibody drug conjugate is novel and effective, and the drug loading capacity of a single drug molecule is improved by using the polyamino acid as the drug conjugate, so that the drug-antibody ratio of the antibody drug conjugate is improved, and the lethality of an anti-tumor drug to HER2 positive breast cancer tumor cells is enhanced.

The invention belongs to the technical field of biology, and particularly relates to a stem cell gel line, a compound containing the stem cell gel line, a catgut embedding needle and application. The stem cell gel line is prepared according to the following steps: preparing a suspension from mesenchymal stem cells, and adding a sodium alginate solution to obtain a stem cell-sodium alginate gel solution; sucking the stem cell-sodium alginate gel liquid, extruding the stem cell-sodium alginate gel liquid into a calcium chloride solution with a relative flow rate in a linear manner at a constant speed, and removing the calcium chloride solution to obtain a stem cell gel line; wherein in the stem cell-sodium alginate gel solution, the final concentration of stem cells is (3-6) * 10 < 6 > / mL, and the final concentration of sodium alginate is 1.5-3wt%. The stem cell gel line provided by the invention can remarkably prolong the activity preservation time of stem cells, can be stored in a line embedding needle, and is convenient to apply.

The trimebutine maleate resin compound slow-release suspension is prepared from the following raw materials in parts by weight: 190 to 210 parts of trimebutine maleate resin compound, 18 to 22 parts of xanthan gum, 0 to 20 parts of tragacanth gum, 15 to 17 parts of citric acid, 4 to 6 parts of propylene glycol and 240 to 260 parts of water. The invention also discloses a preparation method of the trimebutine maleate resin compound slow-release suspension, which comprises the following steps: dissolving xanthan gum and tragacanth gum in water, then sequentially adding citric acid and propylene glycol, uniformly mixing, then adding the trimebutine maleate resin compound, uniformly stirring and mixing to obtain the trimebutine maleate resin compound slow-release suspension. The trimebutine maleate resin compound slow-release suspension is obtained. The trimebutine maleate resin compound sustained-release suspension disclosed by the invention can realize positioned sustained release in the intestinal tract of a human body and continuously exert the drug effect, has good stability and no bitter taste, and improves the taking compliance of a patient.

The present invention relates to the treatment of limb spasm using a modified botulinum neurotoxin A (BoNT / A) comprising a BoNT / A light chain and a translocation domain, and a BoNT / B receptor binding domain (HC domain). Also provided are unit dosage forms of the modified BoNT / A and corresponding kits.

This invention relates to the field of pharmaceutical preparation technology, specifically to a sulfachlorpyridazine sodium-methotrexate suspension, its preparation method, and its application. The sulfachlorpyridazine sodium-methotrexate suspension of this invention comprises the following components per 100 ml: 20-50 g of sulfachlorpyridazine sodium, 4-10 g of methotrexate, 0.1-0.25 g of suspending agent, 0.05-0.125 g of wetting agent, 0.2-0.5 g of antioxidant, 0.1-0.25 g of disodium edetate, and purified water to a final volume of 100 ml. The suspension prepared by this invention can delay the in vivo clearance of sulfachlorpyridazine sodium, prolong the synergistic effect time, and improve its bioavailability; in the treatment of coccidiosis infection in chickens and sheep, it can significantly improve weight gain, reduce intestinal lesion values, rapidly clear oocysts, and maintain a long-lasting protective effect after drug withdrawal.

The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies with a modified isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.

The invention provides oral hydrogel for esophageal mucosa drug delivery and a preparation method and application thereof.The oral hydrogel comprises a first component and a second component, the first component is formed by dispersing polyethylene glycol, polyphenol, sodium alginate and drugs in water, and the second component is formed by dispersing polyethylene glycol, polyphenol, sodium alginate and drugs in water; the second component is formed by dispersing a thermo-sensitive polymer, a tackifier, a water-soluble calcium salt or a water-soluble zinc salt in water; the surface of the first component is covered with the second component, the water-soluble calcium salt or the water-soluble zinc salt reacts with the sodium alginate to convert the first component into a gel state, the first component can be adhered to the wound surface of the esophageal mucosa after being converted into the gel state, and the second component is converted into the gel state under the body temperature condition. The second component plays a physical shielding role after being converted into the gel state, so that the esophageal mucus and the saliva are prevented from being in contact with the first component which is converted into the gel state. The oral administration of the ESD postoperative wound protection hydrogel can be realized, the administration frequency is reduced, and the comfort and compliance of a patient are improved.

This invention discloses the application of Z944 in the preparation of drugs for treating knee osteoarthritis. Z944 can simultaneously promote the repair of knee cartilage and inhibit neuropathic pain, overcoming the shortcomings of existing KOA therapies, such as single target, limited efficacy, and inability to block the core pathological cycle of the disease. The mechanism of action of Z944 lies in its ability to simultaneously inhibit abnormal discharge of pain neurons and block the catabolism signals of chondrocytes, thereby fundamentally intervening in the vicious cycle of cartilage degeneration and pain transmission in knee osteoarthritis. Compared with existing therapies that target only a single pathological link, this invention achieves a synergistic therapeutic effect greater than the sum of its parts (1+1>2). Its efficacy stems from blocking the core mechanism of the disease, thus being more fundamental and lasting.

The invention relates to application of alkaloid in preparation of a T cell immunosuppressor, and belongs to the technical field of application of natural products. The invention discloses an application of a natural product alkaloid of zephyranthes candida in preparation of a T cell immunosuppressor, especially a medicine for acute rejection in allogeneic transplantation, and more particularly a medicine for acute rejection in allogeneic heart transplantation. The alkaloid is used for inhibiting proliferation of T lymphocytes and reducing secretion of inflammatory factors, wherein the T lymphocytes are CD3 + T lymphocytes; the inflammatory factors are a Th1 type inflammatory factor, a Th2 type inflammatory factor and / or a Th17 type inflammatory factor, and the Th1 type inflammatory factor is IL-2, TNF-alpha and IFN-gamma; the Th2 type inflammatory factors are IL-4 (Interleukin-4), IL-6 (Interleukin-6) and IL-10; the Th17 type inflammatory factor is IL-17 (Interleukin-17).

The invention relates to the field of medicine, in particular to a growth hormone fusion protein, a nucleic acid medicine and application of the growth hormone fusion protein and the nucleic acid medicine, the growth hormone fusion protein comprises an ABD structural domain of streptococcus protein G and a growth hormone, and the ABD structural domain is connected with the growth hormone through a linker. The molecular weight of the fusion protein is small, the problems that a large-molecular-weight growth hormone fusion protein is difficult to permeate into a target tissue and the biological activity is low are solved, and the fusion protein has higher biological activity. Compared with a traditional protein drug, the mRNA-LNP drug for coding the fusion protein can directly utilize human body cells to express the protein drug, and the protein drug generated by the mRNA-LNP drug has high activity, can significantly improve the drug effect, and can achieve relatively high biological activity on the premise of low administration dosage.